{"transactions":[{"id":1192090,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":81568,"kind":"person","name":"PASSERI DANIEL R","position":1,"cik":"0001190121","reported_name":"PASSERI DANIEL R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-25T16:00:09.000Z","date":"2025-03-21","kind":"grant","planned":false,"acquired":true,"shares":450000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option becomes exercisable in eight equal semi-annual installments beginning on September 21, 2025."}],"balance_after":450000,"derivative":{"exercise_price":0.99,"expiration_date":"2035-03-20","underlying":"Common Stock","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0000950170-25-044347","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1190121/000095017025044347/ownership.xml","form_type":"4"}},{"id":1326413,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":81568,"kind":"person","name":"PASSERI DANIEL R","position":1,"cik":"0001190121","reported_name":"PASSERI DANIEL R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2024-12-18T16:00:04.000Z","date":"2024-12-16","kind":"purchase","planned":false,"acquired":true,"shares":30000,"price":1.03,"value":30900.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.97 to $1.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range provided."}],"balance_after":164578,"source":{"system":"sec-edgar","filing":"0000950170-24-137860","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1190121/000095017024137860/ownership.xml","form_type":"4"}},{"id":1586334,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":81568,"kind":"person","name":"PASSERI DANIEL R","position":1,"cik":"0001190121","reported_name":"PASSERI DANIEL R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2024-03-08T16:00:09.000Z","date":"2024-03-06","kind":"grant","planned":false,"acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option becomes exercisable in eight equal semi-annual installments beginning on September 6, 2024."}],"balance_after":400000,"derivative":{"exercise_price":1.94,"expiration_date":"2034-03-05","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0000950170-24-028609","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1190121/000095017024028609/ownership.xml","form_type":"4"}},{"id":1805341,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":81568,"kind":"person","name":"PASSERI DANIEL R","position":1,"cik":"0001190121","reported_name":"PASSERI DANIEL R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2023-08-16T16:07:47.000Z","date":"2023-08-14","kind":"purchase","planned":false,"acquired":true,"shares":3000,"price":2.86,"value":8580.0,"ownership":{"direct":true},"balance_after":134578,"source":{"system":"sec-edgar","filing":"0001209191-23-046000","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1190121/000120919123046000/doc4.xml","form_type":"4"}},{"id":1823435,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":81568,"kind":"person","name":"PASSERI DANIEL R","position":1,"cik":"0001190121","reported_name":"PASSERI DANIEL R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2023-07-25T12:28:37.000Z","date":"2023-07-21","kind":"grant","planned":false,"acquired":true,"shares":450000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option grant becomes exercisable in twenty four equal monthly installments beginning on August 21, 2023."}],"balance_after":450000,"derivative":{"exercise_price":4.2,"expiration_date":"2033-07-20","underlying":"Common Stock","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0001209191-23-043276","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1190121/000120919123043276/doc4.xml","form_type":"4"}},{"id":2003135,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":81568,"kind":"person","name":"PASSERI DANIEL R","position":1,"cik":"0001190121","reported_name":"PASSERI DANIEL R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-21T16:59:34.000Z","date":"2023-02-16","kind":"grant","acquired":true,"shares":324000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option becomes exercisable in eight equal semi-annual installments beginning on August 16, 2023."}],"balance_after":324000,"derivative":{"exercise_price":3.21,"expiration_date":"2033-02-15","underlying":"Common Stock","underlying_shares":324000},"source":{"system":"sec-edgar","filing":"0001209191-23-011247","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1190121/000120919123011247/doc4.xml","form_type":"4"}},{"id":2307666,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":81568,"kind":"person","name":"PASSERI DANIEL R","position":1,"cik":"0001190121","reported_name":"PASSERI DANIEL R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Restricted Stock Units","published_at":"2022-04-04T17:29:48.000Z","date":"2022-03-31","kind":"exercise","acquired":false,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit award represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One half of the Restricted Stock Units vested on September 30, 2021 and the balance vested on March 31, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"One half of the Restricted Stock Units vested on September 30, 2021 and the balance vested on March 31, 2022."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001209191-22-022570","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1190121/000120919122022570/doc4.xml","form_type":"4"}},{"id":2307665,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":81568,"kind":"person","name":"PASSERI DANIEL R","position":1,"cik":"0001190121","reported_name":"PASSERI DANIEL R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2022-04-04T17:29:48.000Z","date":"2022-03-31","kind":"gift","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":131578,"source":{"system":"sec-edgar","filing":"0001209191-22-022570","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1190121/000120919122022570/doc4.xml","form_type":"4"}},{"id":2307664,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":81568,"kind":"person","name":"PASSERI DANIEL R","position":1,"cik":"0001190121","reported_name":"PASSERI DANIEL R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2022-04-04T17:29:48.000Z","date":"2022-03-31","kind":"tax_withholding","acquired":false,"shares":32122,"price":4.88,"value":156755.36,"ownership":{"direct":true},"balance_after":141578,"source":{"system":"sec-edgar","filing":"0001209191-22-022570","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1190121/000120919122022570/doc4.xml","form_type":"4"}},{"id":2307663,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":81568,"kind":"person","name":"PASSERI DANIEL R","position":1,"cik":"0001190121","reported_name":"PASSERI DANIEL R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2022-04-04T17:29:48.000Z","date":"2022-03-31","kind":"exercise","acquired":true,"shares":75000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock received upon vesting of a restricted stock unit award."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of common stock received upon vesting of a restricted stock unit award."}],"balance_after":173700,"source":{"system":"sec-edgar","filing":"0001209191-22-022570","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1190121/000120919122022570/doc4.xml","form_type":"4"}},{"id":2315093,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":81568,"kind":"person","name":"PASSERI DANIEL R","position":1,"cik":"0001190121","reported_name":"PASSERI DANIEL R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2022-03-29T16:08:19.000Z","date":"2022-03-25","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1. This stock option grant becomes exercisable in eight equal semi-annual installments beginning September 25, 2022."}],"balance_after":100000,"derivative":{"exercise_price":5.01,"expiration_date":"2032-03-24","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-22-021449","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1190121/000120919122021449/doc4.xml","form_type":"4"}},{"id":2545356,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":81568,"kind":"person","name":"PASSERI DANIEL R","position":1,"cik":"0001190121","reported_name":"PASSERI DANIEL R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Restricted Stock Units","published_at":"2021-10-08T16:00:19.000Z","date":"2021-09-30","kind":"exercise","acquired":false,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit award represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One half of the Restricted Stock Units vested on September 30, 2021 and the balance will vest on March 31, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"One half of the Restricted Stock Units vested on September 30, 2021 and the balance will vest on March 31, 2022."}],"balance_after":75000,"derivative":{"underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001209191-21-060022","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1190121/000120919121060022/doc4.xml","form_type":"4"}},{"id":2545355,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":81568,"kind":"person","name":"PASSERI DANIEL R","position":1,"cik":"0001190121","reported_name":"PASSERI DANIEL R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2021-10-08T16:00:19.000Z","date":"2021-09-30","kind":"tax_withholding","acquired":false,"shares":31677,"price":14.57,"value":461533.89,"ownership":{"direct":true},"balance_after":98700,"source":{"system":"sec-edgar","filing":"0001209191-21-060022","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1190121/000120919121060022/doc4.xml","form_type":"4"}},{"id":2545354,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":81568,"kind":"person","name":"PASSERI DANIEL R","position":1,"cik":"0001190121","reported_name":"PASSERI DANIEL R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2021-10-08T16:00:19.000Z","date":"2021-09-30","kind":"exercise","acquired":true,"shares":75000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock received upon vesting of a restricted stock unit award."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of common stock received upon vesting of a restricted stock unit award."}],"balance_after":130377,"source":{"system":"sec-edgar","filing":"0001209191-21-060022","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1190121/000120919121060022/doc4.xml","form_type":"4"}},{"id":2558698,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":81568,"kind":"person","name":"PASSERI DANIEL R","position":1,"cik":"0001190121","reported_name":"PASSERI DANIEL R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2021-09-27T16:30:15.000Z","date":"2021-09-24","kind":"purchase","acquired":true,"shares":3400,"price":14.721,"value":50051.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.63 to $14.749, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4."}],"balance_after":55377,"source":{"system":"sec-edgar","filing":"0001209191-21-057784","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1190121/000120919121057784/doc4.xml","form_type":"4"}},{"id":2862744,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":81568,"kind":"person","name":"PASSERI DANIEL R","position":1,"cik":"0001190121","reported_name":"PASSERI DANIEL R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-12T17:47:09.000Z","date":"2021-02-10","kind":"grant","acquired":true,"shares":85000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option grant becomes exercisable in eight equal semi-annual installments beginning August 10, 2021."}],"balance_after":85000,"derivative":{"exercise_price":15.55,"expiration_date":"2031-02-09","underlying":"Common Stock","underlying_shares":85000},"source":{"system":"sec-edgar","filing":"0000899243-21-006358","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1190121/000089924321006358/doc4.xml","form_type":"4"}},{"id":3276541,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":81568,"kind":"person","name":"PASSERI DANIEL R","position":1,"cik":"0001190121","reported_name":"PASSERI DANIEL R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Restricted Stock Units","published_at":"2020-02-12T16:49:49.000Z","date":"2020-02-05","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit award represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-half of the restricted stock units vest on September 30, 2021 and the balance vest on March 31, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"One-half of the restricted stock units vest on September 30, 2021 and the balance vest on March 31, 2022."}],"balance_after":150000,"derivative":{"underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001209191-20-008793","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1190121/000120919120008793/doc4.xml","form_type":"4"}},{"id":3276540,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":81568,"kind":"person","name":"PASSERI DANIEL R","position":1,"cik":"0001190121","reported_name":"PASSERI DANIEL R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (right to buy)","published_at":"2020-02-12T16:49:49.000Z","date":"2020-02-05","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option grant becomes exercisable in eight equal semi-annual installments beginning August 5, 2020."}],"balance_after":150000,"derivative":{"exercise_price":16.26,"expiration_date":"2030-02-05","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001209191-20-008793","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1190121/000120919120008793/doc4.xml","form_type":"4"}},{"id":3478597,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":81568,"kind":"person","name":"PASSERI DANIEL R","position":1,"cik":"0001190121","reported_name":"PASSERI DANIEL R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2019-06-25T16:09:47.000Z","date":"2019-06-21","kind":"purchase","acquired":true,"shares":1377,"price":7.26,"value":9997.02,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.25 to $7.26, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4."}],"balance_after":51977,"source":{"system":"sec-edgar","filing":"0001209191-19-038900","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1190121/000120919119038900/doc4.xml","form_type":"4"}},{"id":3496882,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":81568,"kind":"person","name":"PASSERI DANIEL R","position":1,"cik":"0001190121","reported_name":"PASSERI DANIEL R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2019-06-07T16:12:20.000Z","date":"2019-06-06","kind":"purchase","acquired":true,"shares":3000,"price":6.9,"value":20700.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.88 to $6.92, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4."}],"balance_after":50600,"source":{"system":"sec-edgar","filing":"0001209191-19-035525","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1190121/000120919119035525/doc4.xml","form_type":"4"}},{"id":3603852,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":81568,"kind":"person","name":"PASSERI DANIEL R","position":1,"cik":"0001190121","reported_name":"PASSERI DANIEL R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (right to buy)","published_at":"2019-03-08T16:17:00.000Z","date":"2019-03-06","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents a stock option award granted on July 23, 2018 that partially vested upon the achievement of certain performance based conditions as determined by the Compensation Committee of Cue Biopharma, Inc. on March 6, 2019. As of March 6, 2019, 50,000 of these options were vested and exercisable. The remaining 50,000 will become vested and exercisable only upon the achievement of certain performance based conditions."}],"balance_after":100000,"derivative":{"exercise_price":11.54,"expiration_date":"2025-07-23","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-19-018091","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1190121/000120919119018091/doc4.xml","form_type":"4"}},{"id":3603851,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":81568,"kind":"person","name":"PASSERI DANIEL R","position":1,"cik":"0001190121","reported_name":"PASSERI DANIEL R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (right to buy)","published_at":"2019-03-08T16:17:00.000Z","date":"2019-03-06","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option grant becomes exercisable in eight equal semi-annual installments beginning September 6, 2019."}],"balance_after":125000,"derivative":{"exercise_price":6.42,"expiration_date":"2029-03-06","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001209191-19-018091","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1190121/000120919119018091/doc4.xml","form_type":"4"}},{"id":3838050,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":81568,"kind":"person","name":"PASSERI DANIEL R","position":1,"cik":"0001190121","reported_name":"PASSERI DANIEL R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2018-08-20T16:08:52.000Z","date":"2018-08-16","kind":"purchase","acquired":true,"shares":6000,"price":8.085,"value":48510.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.93 to $8.20, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4."}],"balance_after":47600,"source":{"system":"sec-edgar","filing":"0001209191-18-047605","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1190121/000120919118047605/doc4.xml","form_type":"4"}},{"id":3880347,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":81568,"kind":"person","name":"PASSERI DANIEL R","position":1,"cik":"0001190121","reported_name":"PASSERI DANIEL R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2018-06-29T16:10:33.000Z","date":"2018-06-29","kind":"purchase","acquired":true,"shares":1600,"price":11.97,"value":19152.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.95 to $11.97, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4."}],"balance_after":41600,"source":{"system":"sec-edgar","filing":"0001209191-18-040021","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1190121/000120919118040021/doc4.xml","form_type":"4"}}]}